Clinical trial
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
NCT01948180 is registered in ClinicalTrials.gov with Cell Medica Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
- Lead sponsor
- Cell Medica Ltd
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2014
- Completion date
- September 7, 2018
- Enrollment
- 15 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.